Initial experience with golimumab in clinical practice for ulcerative colitis

Initial experience with golimumab in clinical practice for ulcerative colitis

Background: Golimumab is a TNF-blocking agent indicated as a second-line therapy in ulcerative colitis. Purpose: To research the effectiveness and safety of golimumab in patients with ulcerative colitis in clinical practice. Methods: Retrospective study of the effectiveness and safety of golimumab i...

Full description

Bibliographic Details
Main Authors: Luisa Castro-Laria, Federico Argüelles-Arias, Valle García-Sánchez, José Manuel Benítez, Ramón Fernández-Pérez, Ana María Trapero-Fernández, Francisco Gallardo-Sánchez, Héctor Pallarés-Manrique, María Gómez-García, María José Cabello-Tapia, Aurora Talavera-Fabuel, Ana Bejarano-García, Eduardo Leo-Carnerero, Álvaro Hernández-Martínez, Ángel Caunedo-Álvarez, Juan Manuel Herrerías-Gutiérrez
Format: Article
Language:English
Published: Aran Ediciones
Series:Revista Espanola de Enfermedades Digestivas
Subjects:
golimumab
ulcerative colitis
tnf-blocking agent
naive patient
non-naive patient
Online Access:http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1130-01082016000300004&lng=en&tlng=en

Internet

http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1130-01082016000300004&lng=en&tlng=en

Similar Items